Biocon Q2 FY27 Results: Consolidated Net Profit ₹56.70 Crore on Total Income of ₹4,423 Crore
- Earnings
- Pharmaceuticals and biosimilars
Reviewed byKeshav SehgalBlacklitt Research
Biocon (NSE: BIOCON) reported consolidated total income of ₹4,423 crore and net profit of ₹57 crore for the quarter ended 30 Sep 2026, it said in a filing on 04 Nov 2026. Standalone total income was ₹721 crore and standalone net profit ₹92 crore for the same quarter.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹4,423 crore, up 0.8% YoY and 0.7% QoQ
- Net profit: ₹57 crore, down 57.3% YoY and 58.6% QoQ; EPS ₹0.25 basic
- Finance costs: ₹240 crore, down 11.8% YoY and up 12.6% QoQ
Standalone
The company on its own, without its subsidiaries
- Total income: ₹721 crore, up 0.6% YoY and 4.6% QoQ
- Net profit: ₹92 crore, up 29.3% YoY and 75.7% QoQ; EPS ₹0.56 basic
- Other income: ₹91 crore, 12.6% of total income, down 32.2% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 4,423 | 4,389 | +0.8% | 4,391 | +0.7% | |
| Revenue from operations | 4,389 | 4,296 | +2.2% | 4,336 | +1.2% |
| Other income | 35 | 93 | -62.9% | 55 | -36.7% |
| 57 | 133 | -57.3% | 137 | -58.6% | |
| Profit before tax | 55 | 171 | -68.0% | 128 | -57.1% |
| Finance costs | 240 | 272 | -11.8% | 213 | +12.6% |
| Depreciation | 564 | 473 | +19.2% | 547 | +3.0% |
| Tax expense | -2 | 39 | n/a | -9 | +79.3% |
| Net profit margin | 1.28% | 3.03% | -1.74 pp | 3.12% | -1.83 pp |
| EPS, basic (₹) | 0.25 | 0.66 | -62.1% | 0.87 | -71.3% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
The consolidated net profit of ₹57 crore is ₹35 crore lower than the standalone figure of ₹92 crore. The notes report the consolidated profit attributable to shareholders of the company as ₹41.3 crore, with non-controlling interest making up the rest.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 721 | 717 | +0.6% | 689 | +4.6% | |
| Revenue from operations | 631 | 583 | +8.1% | 625 | +1.0% |
| Other income | 91 | 134 | -32.2% | 65 | +40.0% |
| 92 | 71 | +29.3% | 52 | +75.7% | |
| Profit before tax | 120 | 86 | +39.8% | 70 | +71.4% |
| Finance costs | 22 | 67 | -67.4% | 17 | +26.6% |
| Depreciation | 38 | 34 | +13.0% | 38 | -0.5% |
| Tax expense | 28 | 15 | +89.9% | 18 | +58.8% |
| Net profit margin | 12.71% | 9.89% | +2.83 pp | 7.57% | +5.14 pp |
| EPS, basic (₹) | 0.56 | 0.55 | +1.8% | 0.32 | +75.0% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 29.3% to ₹92 crore, slower than the 39.8% rise in profit before tax to ₹120 crore. The tax expense rose to ₹28 crore from ₹15 crore, which is 23.5% of profit before tax this quarter.
Revenue from operations rose 8.1% to ₹631 crore, while other income fell 32.2% to ₹91 crore. Finance costs fell 67.4% to ₹22 crore from ₹67 crore a year earlier. The filing reports no exceptional item for standalone results in the quarter.
Inference
The filing reports that the board approved the results on 4 Nov 2026 and that the statutory auditors issued unmodified limited review reports. The board also recorded a resignation and an appointment for the Chief Technology Officer role, effective 31 Dec 2026 and 1 Jan 2027 respectively.
The filing reports final dividends of ₹0.50 per share by Biocon and ₹1.25 per share by Syngene, both distributed during the quarter. Biocon Biologics Limited became a wholly owned subsidiary on 29 Jun 2026 through a share swap. The filing does not say how the quarter's other income or finance costs changed, or who will lead the technology function beyond the named appointee.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
